MedPath

Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours

Phase 1
Completed
Conditions
Hepatic Impairment
Advanced Cancer
Interventions
Registration Number
NCT00621725
Lead Sponsor
AstraZeneca
Brief Summary

To determine how patients with advanced cancer and various degrees of hepatic impairment will metabolise Cediranib.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
36
Inclusion Criteria
  • Written informed consent
  • Advanced solid tumour (not prostate cancer) for which no standard therapy exists
  • WHO performance status 0-2
  • Bilirubin levels within the target range
Read More
Exclusion Criteria
  • Unstable brain/meningeal metastases
  • Inadequate bone marrow reserve
  • Biochemistry/haematology results outside of required ranges
  • History of significant GI impairment
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1AZD2171-
Primary Outcome Measures
NameTimeMethod
To assess the single dose pharmacokinetics (PK) of Cediranib, in patients with cancer with various degrees of hepatic dysfunction (defined by bilirubin levels).Single dose PK assessed on Day 1 of dosing
Secondary Outcome Measures
NameTimeMethod
Safety/tolerability of Cediranib (single and multiple dose PK)assessed from randomisation to data cut-off (15th July 2010)

Single and multiple dose PK assessed on Day 1 of the single dosing period and Day 21 of the multiple dosing period, respectively (minimum 7 day washout following single dosing)

Trial Locations

Locations (1)

Research Site

🇳🇱

Rotterdam, Netherlands

© Copyright 2025. All Rights Reserved by MedPath